Author:
Santen R. J.,Radisky D. C.,Degnim A.,Frost M. H.,Vachon C. M.,Ghosh K.,Guestini F.,McNamara K. M.,Sasano H.
Funder
National Cancer Institute
Publisher
Springer Science and Business Media LLC
Reference45 articles.
1. Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67(1):7–30
2. Ozanne EM, Wittenberg E, Garber JE, Weeks JC (2010) Breast cancer prevention: patient decision making and risk communication in the high risk setting. Breast J 16(1):38–47
3. Ganz PA, Land SR (2008) Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer. [Review] [34 refs]. Menopause 15(4:Suppl):Suppl-803
4. Fisher B, Costantino JP, Wickerham DL et al (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90(18):1371–1388
5. Fisher MD, O’Shaughnessy J (2002) Anastrozole may be superior to tamoxifen as adjuvant treatment for postmenopausal patients with breast cancer. Clin Breast Cancer 4:269–271
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献